Study Strengthens Case for Prebiotic and Weight Management
Prebiotic specialist Beneo-Orafti (Tienen, Belgium) has announced the results of a new study on overweight and obese subjects and its Orafti Synergy1 oligufructose-enriched inulin.
Prebiotic specialist Beneo-Orafti (Tienen, Belgium) has announced the results of a new study on overweight and obese subjects and its Orafti Synergy1 oligufructose-enriched inulin. Presented in Istanbul at the European Congress on Obesity, the study found that three weeks of a daily dose of Orafti Synergy1 resulted in reduced energy intake in 36 adult subjects.
In the double-blind crossover study, men and women were randomized to receive 6 g of Orafti Synergy1 twice daily (dissolved in a beverage at breakfast and lunch) or placebo for three weeks. Researchers conducting the study found that all subjects reduced energy intake with the inulin product by an average of 3.6%.
Beneo-Orafti says that this result complements previous research on animals and humans. In one human study, 16 g of Orafti Synergy1 daily resulted in 6% reduced energy intake in healthy subjects, reports of reduced hunger feelings, and increased levels of GLP-1 and PYY, two peptides involved in the pathway that signals satiety to the brain.
Steve Mister on CRN's ongoing lawsuit against New York State
October 11th 2024Nutritional Outlook spoke to The Council for Responsible Nutrition's president and CEO, Steve Mister, at its annual meeting, Convergence '24. Mister discussed the latest in its ongoing lawsuit against NY State's law banning the sale of weight management and muscle building products to minors.
